血清碳酸氢盐升高与慢性肾脏病合并代谢性酸中毒患者不良肾脏结局风险降低相关
研究基于美国Optum去标识化医保临床数据集(2007-2019年),纳入24,384例CKD G3-G5期合并代谢性酸中毒患者,中位随访3.7年。采用Cox比例风险模型分析发现,患者个体内血清碳酸氢盐每升高1 mmol/l,复合肾脏结局风险独立于eGFR变化而降低,校正后HR为0.916(95%CI:0.910-0.922;P < 0.001)。
要点
- 个体内血清碳酸氢盐每升高1 mmol/l,复合肾脏结局风险降低,校正后HR为0.916(95%CI:0.910-0.922;P < 0.001)。
- 该关联独立于基线eGFR、血清碳酸氢盐及其他协变量的变化。
- 研究人群为CKD G3-G5期合并代谢性酸中毒(指数血清碳酸氢盐12至<22 mmol/l)的美国患者。
核心结论
- 在美国CKD合并代谢性酸中毒的真实世界人群中,患者个体内血清碳酸氢盐随时间升高且独立于eGFR变化,与CKD进展风险降低相关。
研究设计与样本
- 分析Optum去标识化Integrated Claims-Clinical数据集中2007-2019年美国患者数据,纳入有≥1年既往病历资料、CKD G3至G5期、代谢性酸中毒(指数血清碳酸氢盐12至<22 mmol/l)的患者,共24,384例,中位随访3.7年。
- 主要预测变量为每次指数后门诊血清碳酸氢盐检测时的血清碳酸氢盐变化,作为时间依赖性连续变量评估。
- 主要结局为估算肾小球滤过率(eGFR)较指数下降≥40%或证据提示透析或移植的复合终点,采用Cox比例风险模型评估。
主要发现
- 患者个体内血清碳酸氢盐随时间升高与复合肾脏结局风险降低相关。
- 未校正的血清碳酸氢盐每升高1 mmol/l的风险比(HR)为0.911(95%CI:0.905-0.917;P < 0.001)。
- 校正基线eGFR和血清碳酸氢盐、基线eGFR的时间校正效应及其他协变量后,血清碳酸氢盐每升高1 mmol/l的HR基本不变(0.916 [95%CI:0.910-0.922;P < 0.001])。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Low serum bicarbonate at a single point in time is associated with accelerated kidney decline in patients with chronic kidney disease (CKD). We modeled how changes in serum bicarbonate over time affect incidence of adverse kidney outcomes. METHODS: We analyzed data from Optum's deidentified Integrated Claims-Clinical data set of US patients (2007-2019) with ≥1 year of prior medical record data, CKD stages G3 to G5, and metabolic acidosis (i.e., index serum bicarbonate 12 to <22 mmol/l). The primary predictor of interest was the change in serum bicarbonate, evaluated at each postindex outpatient serum bicarbonate test as a time-dependent continuous variable. The primary outcome was a composite of either a ≥40% decline in estimated glomerular filtration rate (eGFR) from index or evidence of dialysis or transplantation, evaluated using Cox proportional hazards models. RESULTS: A total of 24,384 patients were included in the cohort with median follow-up of 3.7 years. A within-patient increase in serum bicarbonate over time was associated with a lower risk of the composite kidney outcome. The unadjusted hazard ratio (HR) per 1-mmol/l increase in serum bicarbonate was 0.911 (95% confidence interval [CI]: 0.905-0.917; P < 0.001). After adjustment for baseline eGFR and serum bicarbonate, the time-adjusted effect of baseline eGFR and other covariates, the HR per 1-mmol/l increase in serum bicarbonate was largely unchanged (0.916 [95% CI: 0.910-0.922; P < 0.001]). CONCLUSION: In a real-world population of US patients with CKD and metabolic acidosis, a within-patient increase in serum bicarbonate over time independent of changes in eGFR, was associated with a lower risk of CKD progression.
引用
- Tangri N, Ferguson TW, Reaven NL, et al. Increasing Serum Bicarbonate is Associated With Reduced Risk of Adverse Kidney Outcomes in Patients with CKD and Metabolic Acidosis. Kidney Int Rep. 2023. PMID: 37069991. doi:10.1016/j.ekir.2023.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。